Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Why did Cingulate stock skyrocket today?
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts
Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Cingulate Provides Management Team Update
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
Cingulate to Participate in Benzinga All Live Access Event
Cingulate Announces Adjournment of Special Meeting
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Cingulate to Participate in Benzinga All Live Access Event
Cingulate to Attend DCAT Week 2024 in New York City
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
Cingulate Announces Closing of $7.5 Million Public Offering
Cingulate Announces Pricing of $7.5 Million Public Offering
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
Why Is Cingulate (CING) Stock Up 160% Today?
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Cingulate to Host CNS Key Opinion Leader Panel in New York City
Cingulate Inc. to Present at the LD Micro Main Event XVI
Cingulate Inc. To Present at the LD Micro Main Event XVI
Cingulate Announces Closing of $4.0 Million Public Offering